Ospenem 500 mg (Meropenem Hydrate)

Adult administration

As Meropenem Hydrate, administer 0.5 to 1 g (activity) daily divided into 2 to 3 doses via intravenous infusion for at least 30 minutes. In cases of suspected infection in patients with pathogenic pneumonia, peritonitis, or neutropenia, infuse 1 g (activity) every 8 hours. For cystic fibrosis and meningitis, infuse 2 g (activity) every 8 hours.

Child administration

For bacterial meningitis in children older than 3 months, based on the pathogen's sensitivity and the patient's condition, administer 40 mg per kg of body weight via intravenous infusion for at least 30 minutes every 8 hours. Additionally

This medication should not be used in patients with a history of shock resulting from this medication. Additionally, it should not be used in patients taking sodium valproate, as it may lower the blood concentration of valproate, posing a risk of recurrent seizures. Patients who have previously shown allergic reactions to this medication or its components should also avoid receiving this medication. Patients who have had allergic reactions to other carbapenem antibiotics, as well as those who have experienced severe allergic reactions to beta-lactam antibiotics such as penicillin or cephalosporins, should use caution. Careful administration is needed for patients with a history of allergies or family history of bronchial asthma, rashes, or other allergic symptoms. Patients with decreased kidney function may need reduced dosages or extended administration intervals, as this medication may linger in the body causing central nervous system side effects. Patients with epilepsy or central nervous system diseases may experience seizures or consciousness disturbances and should be monitored closely. For patients with severely impaired liver function, use cautiously due to the risk of worsening liver function. Elderly patients may have decreased physiological functions, increasing the potential for side effects, requiring adjustments to dosage and administration intervals while monitoring their condition. Patients who cannot take oral medications or have poor overall health should be monitored closely for vitamin K deficiency symptoms. Children under 3 months of age should avoid using this medication as safety and effectiveness have not been established. This medication can rarely cause severe allergic reactions such as shock or anaphylaxis, necessitating close observation of the patient's condition during administration. If allergy symptoms such as rashes, hives, itching, or fever occur, the administration should be immediately stopped and appropriate treatment received. Various blood abnormalities such as leukopenia, anemia, and thrombocytopenia may occur, requiring regular blood tests with cessation of use if any abnormalities are detected. Liver function abnormalities, acute hepatitis, or jaundice may develop, so regular liver function testing should be conducted, and administration stopped if issues arise. Kidney function may rarely decline or acute renal failure may occur; regular assessment of kidney function is advised, with cessation of use if abnormalities exist. Gastrointestinal side effects such as severe diarrhea or pseudomembranous colitis may arise; if abdominal pain or frequent diarrhea occurs, administration should be stopped immediately. Central nervous system symptoms such as seizures or disturbances in consciousness can occur, especially in patients with kidney or central nervous system disorders, requiring caution. Respiratory side effects may include asthma, dyspnea, or interstitial pneumonia; if symptoms arise, administration should be halted and treatment applied. Severe skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis may rarely occur; administration should cease immediately if skin abnormalities develop. Phenomena such as oral mucositis or candidiasis may occur. Vitamin K deficiency may lead to bleeding tendencies, so careful observation for bleeding symptoms is important. Cardiovascular side effects such as heart failure, arrhythmias, or blood pressure changes have been reported, necessitating appropriate treatment for observed symptoms. Neurological symptoms may include insomnia, hallucinations, or delirium; if any unusual symptoms occur, special attention is required. Local inflammation, pain, or swelling may occur at injection sites, so monitoring of the injection site is necessary. This medication has many drug interactions; special caution is needed when co-administered with probenecid, anticonvulsants, contraceptives, warfarin, etc., and blood concentration should be monitored. For women who are pregnant or may become pregnant, the safety of this medication has not been established, so it should only be administered if the therapeutic benefits outweigh the risks. Breastfeeding women are advised to avoid breastfeeding while on this medication as it can be secreted into breast milk. This medication is ideally not used in infants under 3 months due to unestablished safety and efficacy. After reconstitution, it should be used as soon as possible; if storage is needed, it should be used within 6 hours at room temperature or within 24 hours when refrigerated. This medication is administered only via intravenous injection; prior to administration, it is essential to confirm any past allergic reactions to beta-lactam antibiotics. Additionally, this medication may cause symptoms of rhabdomyolysis, such as muscle pain, muscle weakness, or dark urine; it should be stopped immediately and treated if those symptoms appear.

Serious side effects

• Hives, severe swelling (edema), chest tightness, difficulty breathing → severe allergic reaction
• Rash, blisters, skin peeling, mucosal pain in the mouth/eyes → severe skin abnormal reactions
• Asthma attacks, respiratory issues accompanied by cough and fever, shortness of breath or difficulty breathing → respiratory problems
• Yellowing of the skin or eyes (jaundice), extreme lethargy → liver abnormalities (jaundice)
• Sudden and severe headaches, thunderclap headache, seizures

Mild side effects

• Rash
• hives
• warmth
• erythema
• itching
• fever
• redness
• flushing
• angioedema
• malaise

This medication should be stored in a sealed container to avoid exposure to air and is best kept at room temperature between 1 and 30 degrees Celsius to maintain its effectiveness and prevent deterioration.

Appearance

A colorless, transparent vial filled with crystalline powder ranging from white to light yellow.

Package unit

10 vials/